LYON, France and CAMBRIDGE, Massachusetts, November 5, 2018 (GLOBE NEWSWIRE) – ERYTECH Pharma (ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies from its proprietary platform for encapsulation of red blood cell drugs, today announces a symposium with opinion leaders on the potential of eryaspase in the treatment of pancreatic cancer and triple negative breast cancer, Wednesday, November 7, 2018, from 8:00 am to 11:00 p.m. in New York, USA (13: 00 to 16:00) of Paris).
The event will be moderated by four speakers who will talk about the therapeutic environment and unmet medical needs in pancreatic cancer and triple negative breast cancer before describing in more detail the evolving field of cancer metabolism:
- Prof. Dr. Ahmed Awada, Chief of the Clinical Oncology Clinic of the Jules Bordet Institute in Brussels, Belgium
- Prof. Dr. Javier Cortes, Head of the Breast Cancer Program at the Ramon y Cajal University Hospital in Madrid, Spain
- Prof. Dr. Pascal Hammel, Head of the Digestive Oncology Unit at Beaujon Hospital, linked to Paris VII University in Paris, France
- Prof. Dr. Manuel Hidalgo Medina, Head, Division of Hematology / Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
ERYTECH management will present an overview of the company's clinical pipeline technology and pipeline.
Live webcast information
An audio webcast of the event will be streamed live on the Investors tab of the ERYTECH website. www.erytech.com. The replay of the presentation will be accessible on the ERYTECH website for 30 days after the presentation.
About ERYTECH: www.erytech.com
Founded in Lyon in 2004, ERYTECH is a biopharmaceutical company of clinical stage that develops innovative therapies to combat cancer and orphan diseases. Based on its proprietary platform, ERYCAPS, which uses new technology to encapsulate red blood cell drugs, ERYTECH has developed a portfolio of candidate products targeting markets with high unmet medical needs. The company initially focused on the development of products that target the metabolism of amino acids in cancerous tumors, depriving them of the nutrients they need to survive.
The company's main product, eryaspase, also known as the GRASPA® brand, consists of the encapsulation of an enzyme, L-asparaginase, in donor red blood cells. L-asparaginase destroys asparagine in blood plasma, an essential amino acid for the survival and proliferation of cancer cells. L-asparaginase is a standard component of multidrug chemotherapy used in the treatment of acute lymphoblastic leukemia (ALL), but excessive toxicities have limited clinical development in solid tumors.
Eryaspase demonstrated promising efficacy and tolerability in several studies in ALL, as well as in a second-line study of Phase 1 and Phase 2b in pancreatic cancer. The launch of a Phase 3 main clinical trial is underway for the second-line treatment of pancreatic cancer and a Phase 2 study for triple-negative breast cancer treatment is under preparation. Other programs targeting solid tumors are under development.
ERYTECH produces eryaspase in its own operational production site and is certified by GMP in Lyon and a clinical production site in Philadelphia, United States. ERYTECH is also building a large-scale production site in New Jersey, USA.
In addition to eryaspase, ERYTECH is working on erythemionase, which encapsulates methionine gamma-lyase in red blood cells, targeting the metabolism of amino acids in tumor cells in order to "starve" them. ERYTECH is also considering the use of its ERYCAPS technology for the development of cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma and Bio, CAC Mid & Small, CAC All Negotiable, EnterNext PEA-SME 150 and Next Biotech indices.
Chief Financial Officer and Chief Operating Officer
Mathilde Bohin / Louis-Victor Delouvrier
relationship with investors
|+33 (0) 4 78 74 44 38
+33 (0) 1 44 71 98 52
Forward Looking Statements
This press release contains forward-looking statements, forecasts and estimates with respect to ERYTECH's financial position, results of operations, strategy, clinical and regulatory development plans, objectives and future performance. and the market in which it operates. Some of these statements, forecasts and estimates may be recognized by the use of words such as "believe", "anticipates", "expects", "plans", "plans", "seeks", "estimates", " , "wants" and "continues" and other similar expressions. All statements contained in this press release, in addition to those relating to historical facts, should be considered forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH's product portfolio, clinical development, eryaspase regulatory roadmap, study schedule and clinical trials, announcement of data from those studies and trials, and content and timelines of FDA and EMA decisions with respect to ERYTECH product candidates. Such statements, estimates and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors that were considered reasonable when made, but may not prove to be correct. Real events are difficult to predict and may depend on factors beyond the company's control. With regard to the portfolio of product candidates, there is no guarantee that these candidates will receive the required regulatory approvals or commercial success. As a result, actual results may differ materially from anticipated future results, performance or achievements, as expressed or implied by such forward-looking statements, estimates and estimates. The documents submitted by ERYTECH to the Autorité des Marchés Financiers (AMF) and the Securities and Exchange Commission (SEC), including the Company Registration Document of 2017 registered at the AMF in April 2018 and the company's annual report (Form 20- F) filed with the SEC on April 24, 2018 and the Company's future reports and reports describe these risks and uncertainties. Given these uncertainties, there are no representations as to the accuracy or impartiality of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. ERYTECH undertakes no obligation to update these forward-looking statements, estimates or estimates to reflect any change in the expectations of the Company in relation to them, or any change in the events, conditions or circumstances on which such statements, forecasts or estimates are based, except as required by law.